BiotechTube
Cereno Scientific

Cereno Scientific

CRNO-B.STPhase 2
Gothenburg, Swedencerenoscientific.com

Cereno Scientific is a Swedish clinical-stage biotech company developing first-in-class epigenetic therapies targeting the root causes of rare cardiovascular and pulmonary diseases. The company's lead program, CS1, has demonstrated disease-modifying potential in a Phase IIa trial for PAH and holds FDA Fast Track designation, while its broader HDACi portfolio and preclinical prostacyclin receptor agonist CS585 address significant unmet medical needs. With a strengthened focus on rare diseases, Cereno aims to deliver high treatment value through a business model characterized by relatively shorter development timelines and reduced capital requirements.

Market Cap
$208.8M
+11.7% period
Pipeline
3
drug candidates
Patents
5
granted
Publications
3
indexed

CRNO-B.ST · Stock Price

USD 6.25+0.66 (+11.71%)

Historical price data

AI Company Overview

Cereno Scientific is a Swedish clinical-stage biotech company developing first-in-class epigenetic therapies targeting the root causes of rare cardiovascular and pulmonary diseases. The company's lead program, CS1, has demonstrated disease-modifying potential in a Phase IIa trial for PAH and holds FDA Fast Track designation, while its broader HDACi portfolio and preclinical prostacyclin receptor agonist CS585 address significant unmet medical needs. With a strengthened focus on rare diseases, Cereno aims to deliver high treatment value through a business model characterized by relatively shorter development timelines and reduced capital requirements.

CardiovascularPulmonary

Technology Platform

Cereno's core technology platform focuses on epigenetic modulation through histone deacetylase inhibitors (HDACi) that regulate gene expression to reverse pathological vascular remodeling and fibrosis, complemented by a novel prostacyclin (IP) receptor agonist platform for thrombosis prevention without increased bleeding risk.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
CS1 AdministrationPulmonary Arterial HypertensionPhase 2
CS1-Sodium ValproateThrombosisPhase 1
CS1Pulmonary Arterial HypertensionPre-clinical

Funding History

3
Total raised:$27M
IPO$15MJun 30, 2020
Series A$10MJun 15, 2018
Seed$2MJun 15, 2016

Opportunities

Cereno has significant growth opportunities through its first-in-class epigenetic therapies for rare diseases with high unmet need.
Orphan drug designations provide regulatory advantages and extended market exclusivity, while the company's rare disease focus enables potentially shorter development timelines and premium pricing.
Expansion into additional cardiovascular and pulmonary indications for both HDAC inhibitors and the CS585 platform could substantially broaden the addressable market.

Risk Factors

Key risks include clinical trial failures as the company advances novel mechanisms of action, financial dependency on capital markets as a pre-revenue entity, regulatory hurdles despite orphan designations, and potential competition from larger pharmaceutical companies developing alternative disease-modifying approaches.
The long-term safety profile of epigenetic modulators in chronic cardiovascular diseases remains unproven.

Competitive Landscape

Cereno faces competition from established PAH therapies that primarily provide symptomatic relief (J&J's Uptravi, Bayer's Adempas) but differentiates through disease-modifying potential. In the HDAC inhibitor space for cardiovascular diseases, competition is limited as most development focuses on oncology. For CS585, traditional anticoagulants and existing IP receptor agonists represent competition, but CS585's proposed bleeding safety advantage could provide significant differentiation.